ArticleCell communication and signaling : CCS2026
A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOvarian cancer (OC) is a leading cause of cancer-related mortality in women, largely due to the lack of effective strategies for early detection. Here, we aimed to develop a liquid biopsy assay integrating cell-free DNA (cfDNA) fragmentomic features with serum biomarkers for sensitive OC detection.
methodsPlasma cfDNA from training (n = 91) and independent validation (n = 46) cohorts comprising patients with OC, benign ovarian diseases, and healthy controls, underwent low-coverage whole-genome sequencing to extract copy number variation, fragment size distribution, and Neomer features. Fragmentomic features were first integrated using a stacked machine-learning model and subsequently combined with serum biomarkers CA125 and HE4 to construct the final diagnostic model. Model performance was evaluated in the overall cohort and stratified by disease stage, histological subtype, and tumor grade. An external validation cohort (n = 58) was further used to assess model generalizability.
resultsThe combined model integrating cfDNA fragmentomic features and serum biomarkers demonstrated superior diagnostic accuracy compared with all alternative approaches. In the independent validation cohort, the model achieved an AUC of 0.968 (95% CI: 0.896-0.996), with 85.7% sensitivity and 96.0% specificity. For early-stage OC (FIGO stage I and II), the model yielded an AUC of 0.938 (95% CI: 0.864-0.988), achieving 72.2% sensitivity at a specificity of 96%. Robust performance was observed across histological subtypes (AUC: 0.925-0.991) and tumor grades (AUC: 0.976-0.977). Stratified analyses further confirmed strong discrimination between OC and healthy controls (AUC: 0.995, 95% CI: 0.980-1.000) as well as benign ovarian diseases (AUC: 0.963, 95% CI: 0.921-0.993). In the external validation cohort, the combined model maintained robust diagnostic performance, achieving an AUC of 0.962 (95% CI: 0.898-0.991), with 86.2% sensitivity at 96% specificity.
conclusionsIntegrating cfDNA fragmentomics with CA125 and HE4 via machine learning demonstrates strong potential for ovarian cancer detection and clinicopathological subtyping, supporting future evaluation for clinical translation in population screening and preoperative risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.